Monday, 6 December 2010
Background: The aim of this study was to determine the efficacy of fexofenadine in different dosages for treatment of seasonal allergic rhinitis ( SAR).Method: A placebo-controlled, double blind study was conducted in 114 patients with diagnosis of SAR.They were randomly assigned to received either 60 mg, 120 mg , 180 mg once daily fexofenadine or placebo for one month. Patients were evaluated by using total symptom score ( TSS ) and total nasal score ( TNS ) during and at the end of treatment. Results: Fexofenadine 120-180 mg was significantly more effective than placebo for improvement of SAR signs and symptoms. No statistically significant difference was seen between two dosages ( 120 mg vs. 180 mg ). Conclusion: Once dail 120 mg fexofenadine is an effective and safe treatment for seasonal allergic rhinitis.